Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
BIO Quote, Financials, Valuation and Earnings
Last price:
$320.08
Seasonality move
:
5.89%
Day range:
$311.81 - $321.00
52-week range:
$211.43 - $373.69
Dividend yield:
0%
P/E ratio:
27.23x
P/S ratio:
3.44x
P/B ratio:
1.28x
Volume:
114.3K
Avg. volume:
208.3K
1-year change:
-5.43%
Market cap:
$8.6B
Revenue:
$2.6B
EPS (TTM):
-$24.31
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $348.00, Bio-Rad Laboratories, Inc. has an estimated upside of 8.73% from its current price of $320.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $325.00 representing -1.54% downside risk from its current price of $320.06.
Fair Value
-
According to the consensus of 5 analysts, Bio-Rad Laboratories, Inc. has 8.73% upside to fair value with a price target of $348.00 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories, Inc. has underperformed the S&P 500 by -2.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Bio-Rad Laboratories, Inc. reported revenues of $653M.
Earnings Growth
-
Bio-Rad Laboratories, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories, Inc. reported earnings per share of -$12.70.
Enterprise value:
8.6B
EV / Invested capital:
1.06x
Price / LTM sales:
3.44x
EV / EBIT:
29.93x
EV / Revenue:
3.37x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
25.56x
Price / Operating cash flow:
26.16x
Enterprise value / EBITDA:
17.57x
Gross Profit (TTM):
$1.4B
Return On Assets:
-6.84%
Net Income Margin (TTM):
-26.43%
Return On Equity:
-9.77%
Return On Invested Capital:
-8.14%
Operating Margin:
10.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.7B | $2.6B | $2.6B | $649.7M | $653M | |
| Gross Profit | $1.5B | $1.4B | $1.4B | $355.9M | $342.8M | |
| Operating Income | $397.9M | $344.5M | $287.6M | $94.4M | $66.4M | |
| EBITDA | $599.3M | $541M | $489.9M | $143.5M | $120.6M | |
| Diluted EPS | -$5.85 | -$27.33 | -$24.31 | $23.34 | -$12.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5B | $3.1B | $3.1B | $3.1B | $2.8B | |
| Total Assets | $20B | $12.1B | $11.9B | $10.6B | $9.7B | |
| Current Liabilities | $649.9M | $570.7M | $558.2M | $497.9M | $522.3M | |
| Total Liabilities | $4.6B | $3.6B | $3.5B | $3.1B | $3B | |
| Total Equity | $15.3B | $8.5B | $8.4B | $7.5B | $6.7B | |
| Total Debt | $200.3M | $1.4B | $1.4B | $1.3B | $1.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6B | $411.5M | $491.5M | $163.6M | $120.9M | |
| Cash From Investing | -$110.5M | -$57.5M | -$186M | -$55.6M | -$43M | |
| Cash From Financing | -$311.6M | -$392.6M | -$312.8M | -$96M | -$52.5M | |
| Free Cash Flow | $1.5B | $246.5M | $336.8M | $123.4M | $89.2M | |
BIO
Sector
Market Cap
$8.6B
$28.8M
Price % of 52-Week High
85.65%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
3.69%
-1.32%
1-Year Price Total Return
-5.43%
-20.64%
Beta (5-Year)
1.185
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$323.38
200-day SMA
Buy
Level
$268.84
Bollinger Bands (100)
Buy
Level
269.75 - 317.53
Chaikin Money Flow
Buy
Level
36.8M
20-day SMA
Buy
Level
$315.71
Relative Strength Index (RSI14)
Buy
Level
53.02
ADX Line
Sell
Level
12.54
Williams %R
Neutral
Level
-37.7019
50-day SMA
Buy
Level
$311.12
MACD (12, 26)
Buy
Level
2.92
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
28.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7964)
Buy
CA Score
(Annual)
Level (0.706)
Buy
Beneish M-Score
(Annual)
Level (-3.6752)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.3725)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $348.00.
-
Where Will Bio-Rad Laboratories, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories, Inc. share price will rise to $348.00 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories, Inc.?
Analysts are divided on their view about Bio-Rad Laboratories, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories, Inc. is a Sell and believe this share price will drop from its current level to $325.00.
-
What Is Bio-Rad Laboratories, Inc.'s Price Target?
The price target for Bio-Rad Laboratories, Inc. over the next 1-year time period is forecast to be $348.00 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories, Inc. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories, Inc. shares.
-
What Is The Bio-Rad Laboratories, Inc. Share Price Today?
Bio-Rad Laboratories, Inc. was last trading at $320.08 per share. This represents the most recent stock quote for Bio-Rad Laboratories, Inc.. Yesterday, Bio-Rad Laboratories, Inc. closed at $320.06 per share.
-
How To Buy Bio-Rad Laboratories, Inc. Stock Online?
In order to purchase Bio-Rad Laboratories, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIO
Sector
P/E ratio
27.23x
23.71x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.28x
1.84x
Price / LTM sales
3.44x
1.60x
Growth Metrics
BIO
Sector
Revenue growth
0.5%
4.85%
Earnings growth
-154.41%
11.15%
Revenue (5-year growth)
2.11%
6.45%
Earnings forecast
$1.93
-$0.20
Profitability
BIO
Sector
Profitability FY 2024
$1.4B
$3.6M
Return on invested capital
-8.14%
-30.98%
Return on assets
-6.84%
-27.62%
Return on equity
-9.77%
-36.69%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Jan
28
Balance Sheet
BIO
Sector
Total cash
$1.4B
$27.2M
Short term investments
$1.2B
$25.7M
Total assets
$9.4B
$79.7M
Long term debt
$1.4B
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 105.84% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 1.85% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.66% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
